Acute Intermittent Porphyria Market in depth analysis, development status with future trend

Market Synopsis:

The risk factors associated with acute intermittent porphyria, which include liver cancer (hepatocellular carcinoma), kidney failure, neurological disorders, psychiatric issues, gastrointestinal problems, urinary tract issues, etc. will accelerate the market expansion. The growth of the market is also attributable to the increasing prevalence of the metabolic disorders which is likely to increase further during the assessment period.

The increase in the geriatric population is one of the significant drivers of acute intermittent porphyria market. According to reports, the aging population will almost double up by the end of 2050. Market Research Future (MRFR) has revealed in its latest report that the global acute intermittent porphyria market will thrive steadily at 5.6 % during the forecast period 2017-2023.

Other factors responsible for the market proliferation include developments in the healthcare sector, adoption of latest technologies for diagnosis, drug discoveries for treatment, clinical trials by key players, increased disposable income, population explosion, etc. However, factors that will restrict the market growth across the assessment period include the availability of expensive treatment and poor reimbursement policies in the developing regions.

Regional Analysis:

Europe is the second largest market for acute intermittent porphyria globally. The favorable factors supporting the market expansion in the region are initiatives undertaken by the governments and the availability of funds for research & development activities. The presence of developed economies in the region is also likely to propel the market growth.

Asia Pacific will exhibit the steepest rise in growth of the market. The increasing geriatric population in the region is one of the primary drivers of the market. Asian Development Bank has estimated that by 2050, 15% of the total population of Malaysia will be from over 65 years age group, and in China, the aging population will surpass 300 million. Furthermore, the booming healthcare sector, technological developments, huge patient population, high healthcare expenditure, etc. will favor the market proliferation throughout the projection period.

The Middle East & Africa will exhibit sluggish growth due to limited screening, ignorance of diseases, and poor access to treatment.

Industry Developments:

In January 2018, Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, has announced the expansion of Alnylam Act. The program will include free third-party genetic testing and counseling for Acute Hepatic Porphyrias (AHPs) which include four diseases- acute intermittent porphyria, hereditary deficit of delta-aminolevulinic acid dehydratase, hereditary coproporphyria, and, variegate porphyria.

Article source: https://article-realm.com/article/Sports-Recreation/12744-Acute-Intermittent-Porphyria-Market-in-depth-analysis-development-status-with-future-trend.html